RIGImmune has acquired Subintro, a biotechnology company specializing in the development and delivery of antiviral therapeutics for respiratory diseases caused by RNA viruses.
Building on the foundational work of the company’s Yale co-founders, RIGImmune has developed a specialized understanding of RIG-I, a cytosolic sensor protein and host surveillance pathway that is essential to the innate immune response to RNA viruses and tumor DNA.
“Joining with the experienced Subintro team will allow us to further advance our development of new treatments, prophylactics and vaccine adjuvants for respiratory diseases caused by RNA viruses,” said Susan Sobolov, Ph.D., president of RIGImmune.